BC
CCXI

Bridgefront Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

Bridgefront Capital’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,709
Closed -$230K – 978
2020
Q4 		$230K Buy
+3,709
New +$212K 0.08% 468

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bridgefront Capital's CCXI Position: Q1 2021 in Review

Bridgefront Capital sold out of ChemoCentryx, Inc. (CCXI) in Q1 2021, closing a stake of 3,709 shares — an estimated $230K sold.

Bridgefront Capital first reported a position in CCXI in Q4 2020 and held it in 1 quarter. The position peaked at $230K in Q4 2020. 183 funds tracked by Wall St. Rank hold CCXI as of Q1 2021.

  • Bridgefront Capital reported no remaining ChemoCentryx, Inc. position as of Q1 2021 after selling out during the quarter.
  • Bridgefront Capital sold 3,709 ChemoCentryx, Inc. shares in Q1 2021, an estimated $230K.
  • Bridgefront Capital first reported a position in ChemoCentryx, Inc. in Q4 2020 and held it in 1 quarter.
  • Bridgefront Capital's ChemoCentryx, Inc. position peaked at $230K in Q4 2020.
  • 183 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2021.

Based on Bridgefront Capital's 13F filing for Q1 2021, filed 17 May 2021.